September 9, 2014 — Accuray Inc. announced it has been awarded a new exclusive three-year group purchasing agreement with Premier Inc., covering the CyberKnife M6 and TomoTherapy HDA product portfolios. The Accuray and Premier partnership brings together two companies committed to driving improved patient care through meaningful technical innovation.

"Our goal is to help healthcare providers offer the best treatment option for their patients. The Premier agreement is important because it enables us to partner with a large sales force that has long-standing relationships with hospital-based clinicians and administrators to significantly increase visibility of the CyberKnife and TomoTherapy systems," said Kelly Londy, executive vice president and chief commercial officer of Accuray.

Premier has one of the nation's largest group purchasing organizations (GPOs). Under the new contract, Accuray's precise, clinically proven tumor treatments became available starting Sept. 1 to Premier member hospitals and providers. Premier unites an collective of more than 3,000 hospitals and 110,000 other providers, including oncology centers. In addition, the contract provides Accuray with access to key Premier integrated delivery network partners, where Accuray has had limited historical business presence.

"We believe the Premier agreement will provide improved deal visibility to radiation equipment purchasing decisions earlier in the process and, ultimately, result in new opportunities for Accuray equipment and services," said Joshua H. Levine, president and CEO of Accuray. "The partnership also validates our focus on service excellence and technology performance, and demonstrates the confidence the radiation oncology community has in the unique benefits of the CyberKnife and TomoTherapy Systems."

For more information: www.accuray.com


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
Subscribe Now